Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women’s Interagency HIV Study

HIV Treatment Bulletin - Vol. 8, No. 10, October 2007

A paper in the August 20 2007 edition of AIDS authored by Phyllis Tien and coworkers looked at the incidence of diabetes mellitus (DM) in the Women’s Interagency HIV Study (WIHS). WIHS is an American, nationally representative cohort of HIV-positive women and a comparison group of HIV-negative women.

This was a prospective study between October 2000 and March 2006 of 2088 participants from the WIHS who did not have evidence of DM at enrollment (1524 HIV-positive and 564 HIV-negative).

The study defined Incident DM as either having fasting glucose >/=1.26 g/l, reporting antidiabetic medication, or reporting DM diagnosis (with subsequent confirmation by fasting glucose >/=1.26 g/l or reported antidiabetic medication). All were assessed at twice yearly study visits.

116 HIV-positive women and 36 HIV-negative women developed DM in over 6802 person-years. HIV-positive women reporting no recent antiretroviral therapy (n=25) had a DM incidence rate of 1.53/100 person-years; those reporting HAART containing a PI (n=41) had a rate of 2.50/100 person-years. Those reporting non-PI containing (n=41) HAART a rate of 2.89/100 person-years. HIV-negative women had a DM incidence rate of 1.96/100 person-years.

For HIV-positive women, longer cumulative exposure to NRTI was associated with an increased risk of DM incidence compared with no NRTI exposure: relative hazard (RH) 1.81 [95% confidence interval (CI), 0.83–3.93] for >0 to 3 years exposure and RH 2.64 (95% CI, 1.11–6.32) for >3 years exposure. In this study neither cumulative exposure to an NNRTI nor a PI was associated with DM incidence.

The investigators looked at the rate of DM among HIV-positive women receiving the four most frequently used NRTIs (AZT, abacavir, d4T and 3TC). They found cumulative exposure of >1 year to 3TC was associated with a three fold increase in DM after adjustment.

They concluded: “NRTI are in the backbone of effective ART, and so regular monitoring of fasting glucose levels in HIVinfected patients is warranted. Study of the biological mechanisms by which NRTI might induce disorders in glucose metabolism is a priority.”

2007-10-10
IB070810-13

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.